Compare PNC Financial Services Group Inc. (The) Common Stock (PNC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PNC Financial Services Group Inc. (The) Common Stock vs Sana Biotechnology Inc — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $219.21 (market cap $87.64B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 104.7× Sana Biotechnology Inc's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays a 3.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PNC | SANA | |
|---|---|---|
Market Cap | $87.64B | $836.71M |
Volume | 1,687,662 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $256.97 | $5.92 |
52-Week Low | $178.37 | $2.68 |
Enterprise Value | $144.63B | $749.96M |
Dividend Yield | 3.64% | — |
Typical Hold Time | — | 23 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PNC Financial Services Group Inc. (The) Common Stock
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
